Anti-human immunodeficiency virus synergism zidovudine didanosine dideoxyinosine additive inhibition normal human marrow progenitor cells anti-human immunodeficiency virus HIV activity hemopoietic toxicity zidovudine AZT didanosine dideoxyinosine ddI combination variety cell types AZT potent ddI inhibitor HIV vitro Synergistic inhibition HIV combination agents cells peripheral blood lymphocytes macrophages Toxicity assessment vitro progenitor erythroid granulocyte-macrophage colony-forming assays normal human bone marrow ddI toxic AZT Addition inhibitory concentrations ddI AZT additive inhibition progenitor CFUs vitro findings combinations ddI AZT doses enhanced degree selectivity anti-HIV chemotherapy 